Investor relations
Rights issue 2026
Gradientech announced on 26 February 2026 the decision of the Board to carry out a new issue of shares with preferential rights for existing shareholders of approximately SEK 57 million. The subscription period for the Rights Issue runs from and including 9 March 2026 to and including 23 March 2026.
Annual report 2024
Here you can read about significant events during the year, our target market and the strategy going forward.
AGM 2025
The Annual General Meeting was held on 21 May 21 2025. Here you can find all documentation from the AGM.
Keep up to date - subscribe
About Gradientech
Gradientech is leading the field of ultra-rapid antibiotic susceptibility testing. We develop next-generation diagnostics that provide patients with the right dose of the right medicine at the right time.